Literature DB >> 6882675

Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice.

J Leibovici, Y Stark, M Wolman.   

Abstract

The combined effect of the polysaccharide levan (previously shown to exert a host-dependent as well as direct antitumoural activity) and the cytotoxic agents cyclophosphamide (CY), methotrexate (MTX), vincristine (VINC) and 5-fluoro-uracil (SFU) was studied in Lewis lung carcinoma and AKR lymphoma. Combined chemo- and immunotherapy was applied beginning on the day of tumour cell inoculation. Additive effects were obtained with the combined treatments, compared to single treatments, with all the combinations except MTX-levan in Lewis lung carcinoma, where the combined effect was synergistic. The additive effect was obtained with different doses and routes of chemotherapy, whether local or intraperitoneal. A 2 mg dose of CY combined with levan administered at daily doses of 10 mg, resulted in a 100% prevention of Lewis lung carcinoma growth. It is suggested that the levan may have two beneficial effects: it can exert an inhibitory effect on tumour growth and diminish the deleterious effect of cytotoxic agents on the immune system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6882675      PMCID: PMC2040674     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  22 in total

1.  Inhibition of inflammatory response of skin to Staphylococcus aureus by high polymer levan.

Authors:  M SHILO; M WOLMAN; B WOLMAN
Journal:  Br J Exp Pathol       Date:  1956-04

2.  Effects of route and schedule of administration of high-molecular levan on the growth of AKR lymphoma.

Authors:  Y Sinai; J Leibovici; M Wolman
Journal:  Cancer Res       Date:  1976-05       Impact factor: 12.701

3.  Effects of high-molecular levan on the growth and spread of lymphoma in AKR mice.

Authors:  J Leibovici; Y Sinai; M Wolman; G Davidai
Journal:  Cancer Res       Date:  1975-08       Impact factor: 12.701

4.  Inhibition of 3LL carcinoma of mice by levan treatment.

Authors:  A Borit; J Leibovici; U Sandbank; Y Sinai; M Wolman
Journal:  Isr J Med Sci       Date:  1977-08

5.  Selective suppression of humoral and cellular immunity with cytosine arabinoside.

Authors:  D E Griswold; G H Heppner; P Calabresi
Journal:  Cancer Res       Date:  1972-02       Impact factor: 12.701

6.  B cell mitogenic properties of thymus-independent antigens.

Authors:  A Coutinho; G Möller
Journal:  Nat New Biol       Date:  1973-09-05

7.  Effect of dose and route of Bacillus Calmette-Guérin in chemoimmunostimulation therapy of a murine leukemia.

Authors:  J W Pearson; S D Chaparas; M A Chirigos
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

8.  Effects of isoprinosine, levamisole, muramyl dipeptide, and SM1213 on lymphocyte and macrophage function in vitro.

Authors:  J W Hadden
Journal:  Cancer Treat Rep       Date:  1978-11

9.  Dextran derivatives in single and combination chemotherapy against transplantable mouse ascites and solid tumors.

Authors:  M Suzuki; T Mikami; M Kadowaki; T Matsumoto; S Suzuki
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

10.  Direct antitumor effect of high-molecular-weight levan on Lewis lung carcinoma cells in mice.

Authors:  J Leibovici; G Susskind-Brudner; M Wolman
Journal:  J Natl Cancer Inst       Date:  1980-08       Impact factor: 13.506

View more
  1 in total

1.  Histological changes in spleen and lymph nodes of mice administered cyclophosphamide and levan.

Authors:  A Siegal; S Kopel; J Leibovici
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.